Fig. 1 · Structure

Documents & Downloads

AM251

Cat. No. A12914 CAS 183232-66-8

CB1 receptor antagonist

AM251 is a potent CB1 receptor antagonist (IC50 = 8 nM, Ki = 7.49 nM) that displays 306-fold selectivity over CB2 receptors.

In Stock

Publications for AM251

2 publications citing this product

  1. Vida Mirzaie, .et al. , Iran J Basic Med Sci, 2025, 28(9):1171-1179 PMID: 40809175
  2. Vida mirzaie, .et al. , Research Square, 2024, October

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

AM251 shows CB1 antagonist and inverse agonist activity. In membrane assays it inhibited CP55940-stimulated CB1 responses, while in human CB1-expressing HEK293 cells it increased forskolin-stimulated cAMP accumulation. These endpoints distinguish functional antagonism from inverse agonist behavior. [1,2]

AM251 activity is not confined to CB1. It activated recombinant GPR55 in a membrane GTPγS assay and displaced a mu-opioid receptor radioligand in CHO-hMOR membranes. These model-specific findings limit attribution of an AM251 response to CB1 alone. [1,3]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
CB1

Cellular Effect

Cell Line Activity Value Description Reference
HEK293 EC50 0.63 μM Agonist activity at human GPR55 expressed in HEK293 cells assessed as increase in oscillation Ca2+ transients by fura-2 dye based fluorescence analysis 10.1039/C3MD00394A
Sf9 EC50 0.07 μM Inverse agonist activity at human CB1 receptor expressed in Sf9 cells coexpressing Gbeta1gamma2 and RSG4 assessed as degradation of [gamma-33P]GTP after 20 mins by steady-state GTPase assay [PMID: 25096297]

AM251 Research Summary

This section summarizes 3 in vitro studies and 2 in vivo studies of AM251 from 4 published references. In vitro models include intact HEK293 cells expressing human CB1.

AM251 In Vitro Studies

In human CB1-expressing HEK293 cells, AM251 increased forskolin-stimulated cAMP, whereas the neutral-antagonist comparator AM4113 did not. The published curves each show one assay performed in triplicate; they do not establish independent biological replication. [2]

Membrane functional profile at GPR55, CB1 and CB2

Biochemical assay · Human GPR55 expressed in HEK293s membranes; commercially supplied CB1 and CB2 receptor membranes [1]

AM251 activated GPR55 but antagonized CP55940-stimulated responses at CB1 and CB2. These are functional assay potencies, not binding affinities or treatment doses.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
GPR55-stimulated GTPγS bindingEC50 39 ± 3 nM (mean ± s.e.m.; five independent experiments)[1]
Maximal GPR55 GTPγS responseEmax 88 ± 4% (mean ± s.e.m.; five independent experiments; Table 1)[1]
Inhibition of CP55940 EC80 response at CB1IC50 8 ± 1 nM (mean ± s.e.m.; five independent experiments)[1]
Inhibition of CP55940 EC80 response at CB2IC50 2915 ± 102 nM (mean ± s.e.m.; five independent experiments)[1]

Literature-Reported Treatment Conditions

Exposure duration
45 min
Method
[35S]-GTPγS binding at 30°C; antagonist activity tested against the CP55940 EC80 determined that day
Reported limits
Compound vehicle and supplier for AM251 are not specified in the read methods; exact screening concentration series not given in tables.
Methods and source locations

Compound reported in the paper: AM251; Compound label in the paper: AM251

Results apply to the reported research material and model; they do not validate an Adooq batch.

Tables 1–2 (AM251 rows and footnotes); Methods: Cell transfection and membrane preparation, [35S]-GTPγS binding assay; Results: GPR55 binds and is activated by cannabinoid ligands

GPR55-stimulated GTPγS binding: Membrane [35S]-GTPγS binding — Table 1, AM251 row and footnote

Maximal GPR55 GTPγS response: Membrane [35S]-GTPγS binding — Table 1, AM251 row, column heading and footnote

Inhibition of CP55940 EC80 response at CB1: Functional antagonism, not receptor-binding Ki — Table 2, AM251 row and footnote

Inhibition of CP55940 EC80 response at CB2: Functional antagonism, not receptor-binding Ki — Table 2, AM251 row and footnote

Inverse agonist response in human CB1-expressing cells

Cell-based study · Intact HEK293 cells expressing human CB1 [2]

AM251 increased forskolin-stimulated cAMP accumulation; the neutral-antagonist comparator AM4113 did not. Figure 1 shows one assay in triplicate per compound, limiting inference about independent replication.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Forskolin-stimulated cAMP accumulationDirection Increased versus forskolin baseline; Figure 1 represents one assay performed in triplicate[2]

Literature-Reported Treatment Conditions

Exposure duration
5 min
Method
Competitive protein-binding cAMP assay at 37°C in the presence of forskolin
Co-treatment
Forskolin assay stimulation; AM4113 and SR141716A tested separately as comparators
Reported limits
Forskolin concentration and AM251 stock vehicle not specified in the read assay methods. No precise EC50 extracted from the curve.
Methods and source locations

Compound reported in the paper: AM251; Compound label in the paper: AM251

Results apply to the reported research material and model; they do not validate an Adooq batch.

Experiment 1b methods; Experiment 1 results; Figure 1b with panels a/c as comparators and caption; Drugs

Forskolin-stimulated cAMP accumulation: Competitive protein-binding assay; image viewed, no exact curve-derived maximum or EC50 adopted — Experiment 1 results; Figure 1b and caption

Direct binding to recombinant human mu-opioid receptors

Biochemical assay · Membrane homogenates from CHO cells stably expressing human MOR, without CB1 receptors [3]

AM251 displaced the MOR radioligand in a recombinant system, supporting a direct off-target binding interaction. This selected experiment measures affinity; it does not by itself establish functional antagonism or an in-vivo effect.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Affinity at human mu-opioid receptorsKi 251 ± 69 nM (mean ± SEM; N=4 separate experiments; assays in triplicate per Methods 2.9)[3]

Literature-Reported Treatment Conditions

Exposure duration
90 min
Method
Competition against 1 nM [3H]DAMGO at room temperature; nonspecific binding defined with 10 µM naloxone
Co-treatment
Radioligand-binding assay; morphine, rimonabant and AM281 were separate comparator competitors
Reported limits
AM251 vehicle not stated for this binding assay in the read methods. Exact concentration series is graphed, not transcribed.
Methods and source locations

Compound reported in the paper: AM251; Compound label in the paper: AM-251

Results apply to the reported research material and model; they do not validate an Adooq batch.

Methods 2.1, 2.3–2.5, 2.9; Results 3.3; Table 1 human MOR column; Figure 4/caption

Affinity at human mu-opioid receptors: Competition binding; Cheng–Prusoff conversion of IC50 to Ki as reported by authors — Results 3.3; Table 1; Figure 4 and Methods 2.9

AM251 In Vivo Studies

In male Lewis rats, daily 1 mg/kg or intermittent 5 mg/kg intraperitoneal AM251 reduced food intake and body-weight gain during treatment. Both schedules were followed by rebound hyperphagia. In a separate temperature challenge, AM251 attenuated THC-induced hypothermia at 45 min, with no significant antagonism at 48 or 96 h. The longer feeding effect therefore cannot be equated with sustained blockade in this temperature assay. [4]

Repeated-dose feeding and body-weight time course in rats

Animal study · Male Lewis rats, 440–540 g; palatable Ensure Plus liquid diet available 17 h/day [4]

Both dosing schedules reduced food intake and body-weight gain relative to vehicle. Food-intake differences between schedules were nonsignificant. Rebound hyperphagia followed treatment cessation; the finding does not establish persistent weight loss after withdrawal.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Cumulative food intake during days 1–15Mean ± s.e.m. Vehicle 967 ± 47 g; 1 mg/kg/day 762 ± 31 g; 5 mg/kg every 5 days 750 ± 24 g; both AM251 groups P<0.001 versus vehicle; between schedules P>0.05[4]
Food intake after treatment withdrawalDirection Hyperphagia relative to vehicle on day 21 and days 23–28 in both schedules (P<0.05)[4]

Conditions shared by the study groups

Route
Intraperitoneal
Vehicle
2% DMSO, 1% Tween 80, 97% saline
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Daily AM251
1 mg/kg
Vehicle daily, n=5Reduced cumulative food intake and body-weight gain relative to vehicle; rebound hyperphagia after cessation.[4]
Intermittent AM251
5 mg/kg
Vehicle daily, n=5Reduced cumulative food intake and body-weight gain relative to vehicle; rebound hyperphagia after cessation.[4]
Daily AM251
Model: Male Lewis rats; n=6
Frequency: Daily
Treatment course: Days 1–15
Intermittent AM251
Model: Male Lewis rats; n=6
Frequency: Every 5 days
Treatment course: Days 1, 6 and 11; 15-day treatment comparison
Methods and source locations

Compound reported in the paper: AM251; Compound label in the paper: AM 251

Results apply to the reported research material and model; they do not validate an Adooq batch.

Methods: Animals, Drugs, AM 251 and food intake, Statistics; Results: Food intake and Body weight; Figure 1a–d/caption

Cumulative food intake during days 1–15: One-way independent-measures ANOVA and Newman–Keuls comparisons — Results: Food intake, cumulative intake paragraph; Figure 1b/caption

Food intake after treatment withdrawal: Daily intake records; original text values, no curve interpolation — Results: Food intake; Figure 1a/caption

Daily AM251 · Methods: Animals, Drugs, AM 251 and food intake, Statistics; Results: Food intake and Body weight; Figure 1a–d/caption

Intermittent AM251 · Methods: Animals, Drugs, AM 251 and food intake, Statistics; Results: Food intake and Body weight; Figure 1a–d/caption

Duration of antagonism of THC-induced hypothermia

Animal study · Male Lewis rats, 300–350 g; separate challenge groups [4]

A single AM251 dose attenuated THC-induced hypothermia at 45 min, but did not significantly antagonize the response at 48 or 96 h. This temperature endpoint does not measure receptor occupancy or establish the mechanism of the longer feeding response.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Change from baseline core temperature integrated over 75 min after THCAntagonism time course Attenuation at 45 min (P<0.01, unpaired t-test); no significant antagonism at 48 or 96 h[4]

Conditions shared by the study groups

Route
Intraperitoneal
Frequency
One AM251 pretreatment; one THC challenge per interval group
Treatment course
THC 45 min, 48 h or 96 h after AM251; temperature sampled for 75 min after THC
Vehicle
AM251: 2% DMSO, 1% Tween 80, 97% saline; THC: 44% DMSO, 1% Tween 80, 55% saline
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
AM251 pretreatment plus THC
AM251 5 mg/kg once; THC 8 mg/kg challenge
Vehicle pretreatment plus THC as shown in Figure 3Attenuated hypothermia at 45 min; no significant antagonism at 48 or 96 h.[4]
AM251 pretreatment plus THC
Model: Male Lewis rats; AM251 challenge groups n=4 at 45 min, n=5 at 48 h, n=5 at 96 h
Reported limits: Vehicle comparator group sizes are not specified in the read hypothermia methods/caption.
Methods and source locations

Compound reported in the paper: AM251; Compound label in the paper: AM 251

Results apply to the reported research material and model; they do not validate an Adooq batch.

Methods: Animals, Drugs, AM 251 and THC-induced hypothermia; Results: AM 251 and thermogenesis; Figure 3/caption

Change from baseline core temperature integrated over 75 min after THC: Temperature area under curve; means ± s.e.m. shown in figure; no exact bar values extracted — Figure 3/caption; Results: AM 251 and thermogenesis

AM251 pretreatment plus THC · Methods: Animals, Drugs, AM 251 and THC-induced hypothermia; Results: AM 251 and thermogenesis; Figure 3/caption

Specifications

Manufacturer Adooq Bioscience
Actions Antagonist
CAS Number 183232-66-8
Applications CB1 receptor antagonist
Formula C22H21Cl2IN4O
Molecular Weight 555.24
SMILES
CC1=C(N(N=C1C(=O)NN2CCCCC2)C3=C(C=C(C=C3)Cl)Cl)C4=CC=C(C=C4)I

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 39 mg/mL (70.24 mM)
Water Insoluble
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

In Vivo Preparation

Concentration
7 mg/mL
Vehicle
1% DMSO+30% polyethylene glycol+1% Tween 80

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

AM251 Research References

  1. [1] Ryberg E, Larsson N, Sjögren S, et al. The orphan receptor GPR55 is a novel cannabinoid receptor British Journal of Pharmacology (2007). PMID: 17876302 DOI: 10.1038/sj.bjp.0707460 Source material
  2. [2] Sink KS, McLaughlin PJ, Wood JA, et al. The novel cannabinoid CB1 receptor neutral antagonist AM4113 suppresses food intake and food-reinforced behavior but does not induce signs of nausea in rats Neuropsychopharmacology (2008). PMID: 17581535 DOI: 10.1038/sj.npp.1301476 Source material
  3. [3] Seely KA, Brents LK, Franks LN, et al. AM-251 and rimonabant act as direct antagonists at mu-opioid receptors: implications for opioid/cannabinoid interaction studies Neuropharmacology (2012). PMID: 22771770 DOI: 10.1016/j.neuropharm.2012.06.046 Source material
  4. [4] Chambers AP, Koopmans HS, Pittman QJ, et al. AM 251 produces sustained reductions in food intake and body weight that are resistant to tolerance and conditioned taste aversion British Journal of Pharmacology (2006). PMID: 16258524 DOI: 10.1038/sj.bjp.0706439 Source material

Publications

2 publications citing this product

  1. Vida Mirzaie, .et al. , Iran J Basic Med Sci, 2025, 28(9):1171-1179 PMID: 40809175
  2. Vida mirzaie, .et al. , Research Square, 2024, October

Added to your cart

View Cart Checkout
Loading...